Science of psychedelics
Explanation
The science of psychedelics studies the cognitive, emotional, neurobiological and therapeutic effects of substances such as LSD, psilocybin (mushrooms), DMT, mescaline (peyote, San Pedro), MDMA, ayahuasca, ibogaine. After a first wave of research in the 1950s and 60s (Hofmann, Leary, Grof, Pahnke), the field was politically suppressed by the war on drugs. Since the late 1990s, it has experienced a psychedelic renaissance with rigorous research at universities such as Johns Hopkins, Imperial College, NYU, MAPS.
Typical effects at psychedelic doses include perceptual alterations (synaesthesias, intensification, visual geometries), modifications of the sense of self (temporary ego dissolution, experiences of unity), profound emotional changes (openness, awe, fear, ecstasy), processes of psychological insight, and, in some cases, significant mystical experiences with potential for lasting personal change. Duration varies according to the substance (DMT minutes, psilocybin 4-6 hours, LSD 8-12 hours, ibogaine up to 36).
Contemporary therapeutic findings are remarkable. Studies on psilocybin have shown efficacy in treatment-resistant depression, anxiety associated with terminal illness, addictions (tobacco, alcohol). MDMA has shown efficacy in post-traumatic stress disorder with results that have led the FDA to grant breakthrough therapy status. Ayahuasca and ibogaine are being investigated for depression and addictions, respectively. Effects tend to be long-lasting after few sessions, in combination with psychotherapy.
Neuroscientific findings led by Robin Carhart-Harris and others show that classical psychedelics (mainly acting on serotonergic 5-HT2A receptors) reduce default-mode-network activity, increase global brain entropy, weaken predictive-processing hierarchies, and enable patterns of communication between brain regions that are normally less connected. This brain disinhibition is associated with the phenomenology of openness, novelty, psychological plasticity.
For the theory of consciousness, psychedelics are a privileged experimental window. They allow observation of controlled and robust variations in the phenomenology of consciousness, linked to well-characterised neural changes. They illuminate questions such as the nature of the self (its temporary dissolution without loss of consciousness shows that consciousness does not require ego), the relations between predictive control and experience (REBUS theory), and the role of serotonergic receptors in modulating subjectivity.
Open questions are many: what makes induced mystical experiences so therapeutically powerful?, are the subjective experiences themselves what heal or are they only correlates of neural changes?, how to integrate the experiences into daily life?, what psychological risks exist and how to avoid them?, what legal and clinical frameworks are appropriate? The field is growing rapidly, with decriminalisation in some jurisdictions, ongoing clinical approvals, and a cultural debate on the place of psychedelics in contemporary society.
Strengths
- Growing clinical evidence for treatment-resistant depression and other conditions.
- Productive and testable neuroscientific framework (entropy, DMN).
- Reopens the rigorous study of mystical experiences.
- Dialogue with indigenous and contemplative traditions.
Main critiques
- Psychological risks in vulnerable profiles.
- Expectancy biases in open-label studies.
- Cultural appropriation of indigenous medicines.
- Pending regulatory and safety integration at scale.